Pattern of Retinopathy: Although the locus of toxic damage is parafoveal in many eyes, Asian patients often show an extramacular pattern of damage. Dose: We recommend a maximum daily HCQ use of 5.0 mg/kg real weight, which correlates better with risk than ideal weight. Fundus plaquenil Ara hydroxychloroquine Lupus on plaquenil Can you use plaquenil if allergic to quinine Background Generally, the plaquenil eye exam is something everyone here has done. These are the patients where you need to knock out that extra 10-2 in your exam.except that may not be true anymore. What is plaquenil used for? Plaquenil is the brand name for the prescription drug hydroxychloroquine. It's used to treat and prevent malaria infection, and to reduce symptoms and progression of autoimmune diseases such as. To gather the clinical information required to screen for early detection of plaquenil-induced toxic maculopathy, the following diagnostic program could be considered, with emphasis on OCT testing first and visual field analysis second Spectral-domain OCT testing; Threshold visual field examination with a 10-2 testing strategy Risk of Toxicity: The risk of toxicity is dependent on daily dose and duration of use. There are no similar demographic data for CQ, but dose comparisons in older literature suggest using 2.3 mg/kg real weight. 10-2 plaquenil Hydroxychloroquine And Chloroquine Screening 2016 AAO., Plaquenil Hydroxychloroquine - Side Effects, Dosage. Plaquenil patient assistance programQuinacrine and hydroxychloroquine lupus panniculitis A risk factor for Plaquenil hydroxychloroquine retinotoxicity is a daily dose that exceeds 5.0 mg of drug per kg of body weight. The tool on the right simply calculates this threshold based on a ppatient’s real body weight. It’s important to understand that the daily dose is only one risk factor for plaquenil retinotoxicity. Plaquenil Risk Calculators. Plaquenil-Induced Toxic Maculopathy - Decision-Maker PLUS. DailyMed - PLAQUENIL- hydroxychloroquine sulfate tablet. One year later, a 10-2 HVF was obtained that showed dense paracentral scotomas bilaterally Figure 2, despite normal visual acuity, Amsler grid, and color vision testing. Upon the detection of the visual field defects, the hydroxychloroquine was stopped. The position statement on hydroxychloroquine retinopathy provided by the American College of Rheumatology ACR—and reviewed by the American Academy of Ophthalmology AAO in Ophthalmology 2002; 177–82— recommends that all individuals starting HCQ have a complete baseline ophthalmologic exam within the first year of treatment, to. Of 2361 patients who had taken hydroxychloroquine continuously for at least 5 years and who had 10-2 visual fields or SD-OCT, 177 7.5% showed clear signs of retinal toxicity. None of the primary medical indications for hydroxychloroquine therapy were significantly associated with an increased prevalence of retinal toxicity.